Phase II RCT in endocrine-refractory metastatic HR+/HER2- breast cancer: taselisib plus tamoxifen vs placebo plus tamoxifen improved median PFS (4.8 vs 3.2 months; HR 0.69, 80% CI 0.49-0.98), but toxicity was significant (diarrhoea 40%).
RCT
Voorthuis et al. PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results